You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Boehringer Ingelheim
Merck
Mallinckrodt
AstraZeneca

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

DETROL LA Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Detrol La, and what generic alternatives are available?

Detrol La is a drug marketed by Pharmacia And Upjohn and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and thirty-seven patent family members in forty-four countries.

The generic ingredient in DETROL LA is tolterodine tartrate. There are twenty-three drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the tolterodine tartrate profile page.

US ANDA Litigation and Generic Entry Outlook for Detrol La

A generic version of DETROL LA was approved as tolterodine tartrate by MYLAN on October 31st, 2013.

  Start Trial

Drug patent expirations by year for DETROL LA
Drug Prices for DETROL LA

See drug prices for DETROL LA

Drug Sales Revenue Trends for DETROL LA

See drug sales revenues for DETROL LA

Recent Clinical Trials for DETROL LA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of California, San FranciscoPhase 4
Astellas Scientific & Medical Affairs, Inc.N/A
Astellas Pharma Global Development, Inc.Phase 4

See all DETROL LA clinical trials

Pharmacology for DETROL LA
Paragraph IV (Patent) Challenges for DETROL LA
Tradename Dosage Ingredient NDA Submissiondate
DETROL LA CAPSULE, EXTENDED RELEASE;ORAL tolterodine tartrate 021228 2007-07-30

US Patents and Regulatory Information for DETROL LA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn DETROL LA tolterodine tartrate CAPSULE, EXTENDED RELEASE;ORAL 021228-001 Dec 22, 2000 AB RX Yes No   Start Trial   Start Trial   Start Trial
Pharmacia And Upjohn DETROL LA tolterodine tartrate CAPSULE, EXTENDED RELEASE;ORAL 021228-002 Dec 22, 2000 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Pharmacia And Upjohn DETROL LA tolterodine tartrate CAPSULE, EXTENDED RELEASE;ORAL 021228-001 Dec 22, 2000 AB RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DETROL LA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn DETROL LA tolterodine tartrate CAPSULE, EXTENDED RELEASE;ORAL 021228-002 Dec 22, 2000   Start Trial   Start Trial
Pharmacia And Upjohn DETROL LA tolterodine tartrate CAPSULE, EXTENDED RELEASE;ORAL 021228-001 Dec 22, 2000   Start Trial   Start Trial
Pharmacia And Upjohn DETROL LA tolterodine tartrate CAPSULE, EXTENDED RELEASE;ORAL 021228-001 Dec 22, 2000   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for DETROL LA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0325571 21/1998 Austria   Start Trial PRODUCT NAME: TOLTERODIN, SEINE SALZE, RACEMATE UND ENANTIOMERE; NAT. REGISTRATION NO/DATE: 1-22389 UND 1-22390 19980210; FIRST REGISTRATION: SE 13475 UND 13476 19970905
0325571 1998C0031 Belgium   Start Trial PRODUCT NAME: TOLTERODINI-L-TARTRAS (=TOLTERODINUM); NATL REGISTRATION NO/DATE: 277 IS 301 F 3 19980309; FIRST REGISTRATION: SE 13475 19970905
0325571 C980020 Netherlands   Start Trial PRODUCT NAME: TOLTERODINE, DESGEWENST IN DE VORM VAN EEN ZOUT MET EEN FYSIOLO GISCH ACCEPTABEL ZUUR, IN HET BIJZONDER TOLTERODINE L-TARTRAAT; NAT. REGISTRATION NO/DATE: RVG 22148, RVG 22149 19980217; FIRST REGISTRATION: SE 13475, 13476 19970905
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Boehringer Ingelheim
Merck
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.